RU2018138688A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018138688A3 RU2018138688A3 RU2018138688A RU2018138688A RU2018138688A3 RU 2018138688 A3 RU2018138688 A3 RU 2018138688A3 RU 2018138688 A RU2018138688 A RU 2018138688A RU 2018138688 A RU2018138688 A RU 2018138688A RU 2018138688 A3 RU2018138688 A3 RU 2018138688A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662318929P | 2016-04-06 | 2016-04-06 | |
| US62/318,929 | 2016-04-06 | ||
| PCT/US2017/026280 WO2017176960A1 (en) | 2016-04-06 | 2017-04-06 | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018138688A RU2018138688A (ru) | 2020-05-19 |
| RU2018138688A3 true RU2018138688A3 (enExample) | 2020-08-31 |
| RU2799332C2 RU2799332C2 (ru) | 2023-07-04 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| IL262177A (en) | 2018-11-29 |
| AU2017246455A1 (en) | 2018-10-25 |
| KR20180133461A (ko) | 2018-12-14 |
| US20230098494A1 (en) | 2023-03-30 |
| EP3440080A4 (en) | 2020-01-22 |
| RU2018138688A (ru) | 2020-05-19 |
| US20190330213A1 (en) | 2019-10-31 |
| CA3020287A1 (en) | 2017-10-12 |
| BR112018070586A2 (pt) | 2019-02-05 |
| SG11201808830YA (en) | 2018-11-29 |
| US20200017507A1 (en) | 2020-01-16 |
| BR112018070586A8 (pt) | 2023-03-14 |
| EP3440080A1 (en) | 2019-02-13 |
| CN109311887A (zh) | 2019-02-05 |
| WO2017176960A1 (en) | 2017-10-12 |
| US20170349598A1 (en) | 2017-12-07 |
| AU2017246455B2 (en) | 2021-09-30 |
| MX2018012211A (es) | 2019-03-28 |
| KR20230104752A (ko) | 2023-07-10 |
| CN109311887B (zh) | 2022-09-13 |
| US9840510B1 (en) | 2017-12-12 |
| US11192892B2 (en) | 2021-12-07 |
| IL262177B (en) | 2022-06-01 |
| JP2019510790A (ja) | 2019-04-18 |
| JP7038063B2 (ja) | 2022-03-17 |
| US12116369B2 (en) | 2024-10-15 |
| US10934298B2 (en) | 2021-03-02 |
| KR20230104752A9 (ko) | 2024-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018068177A2 (enExample) | ||
| BR112018003417A2 (enExample) | ||
| BR112019009201A2 (enExample) | ||
| BR112019002665A2 (enExample) | ||
| BR112018004986A2 (enExample) | ||
| BR112019008105A2 (enExample) | ||
| BR122020022459A2 (enExample) | ||
| BR112019009263A2 (enExample) | ||
| BR112019000402A2 (enExample) | ||
| BR212018070320U2 (enExample) | ||
| BR112019009203A2 (enExample) | ||
| BR112019008501B1 (pt) | Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador | |
| BR122022000560B1 (pt) | Inibidor da aldosterona sintase, seu uso e seu processo de preparação, e composição farmacêutica | |
| BR112019003116B1 (pt) | Configuração de símbolo de rajada comum de uplink | |
| BR112019001727B1 (pt) | Método para comunicação sem fio realizado por um equipamento de usuário, método para comunicação sem fio realizado por uma estação-base, equipamento de usuário para comunicação sem fio, estação-base para comunicação sem fio, e memória | |
| BR112019000061B1 (pt) | Comutação e modulação de splicing de pré-mrna compreendendo porções de arcabouço bicíclico, com características melhoradas para o tratamento de distúrbios genéticos | |
| BR112018076493B1 (pt) | Sistemas e métodos para detecção de posição de feixe de luz | |
| BR112018073794B1 (pt) | Partícula, método de geração da partícula, vacina ou composição farmacêutica | |
| BR112018072681B1 (pt) | Anticorpos anti-il-1r3 humanizados, fragmento ou derivado do mesmo, seu uso e composição farmacêutica | |
| BR122026002225A2 (pt) | Métodos para diagnosticar uma doença ou condição e para determinar dpp3 ativo em uma amostra de fluido corporal | |
| BR122026002520A2 (pt) | Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno | |
| BR212019008871U2 (enExample) | ||
| BR112019006736A2 (enExample) | ||
| BR102016018018A2 (enExample) | ||
| CN303576500S (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |